Skip to main content

Advertisement

Table 3 Summary of Adverse Events

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Adverse EventAny GradeGrade 3 or 4
number of patients (percent)
Fatigue or asthenia17 (60.7)0 (0)
Anemia12 (42.9)3 (10.7)
Decreased appetite12 (42.9)0 (0)
Nausea11 (39.3)0 (0)
Arthralgia9 (32.1)0 (0)
Vomiting7 (25.0)0 (0)
Abdominal pain5 (17.9)2 (7.1)
Constipation5 (17.9)0 (0)
Dysgeusia5 (17.9)0 (0)
Neutropenia5 (17.9)0 (0)
Thrombocytopenia4 (14.3)1 (3.6)
Back pain4 (14.3)0 (0)
Diarrhea3 (10.7)0 (0)
Dizziness3 (10.7)0 (0)
Upper abdominal pain3 (10.7)0 (0)
Cough3 (10.7)0 (0)
Dyspnea1 (3.6)0 (0)
Headache0 (0)0 (0)
Dyspepsia0 (0)0 (0)
Newly observed
 Abdominal distention4 (14.3)0 (0)
 Decreased blood pressure1 (3.6)0 (0)
 Skin rash1 (3.6)0 (0)
 Increased body hair1 (3.6)0 (0)
 Thirsty1 (3.6)0 (0)
 Burning sensation of stomach1 (3.6)0 (0)
 Leg swelling1 (3.6)0 (0)
Led to discontinuation of intervention3 (10.7)
Led to dose reduction8 (28.6)
Led to dose interruption4 (14.3)
  1. Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE), version 4.0